Bromesep Drug Interactions

Additive CNS depression may occur when BROMESEP is administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol. Thus, concomitantly use is not recommended. Patients already receiving another CNS depressant should not undertake self-medication with this product without first consulting a physician. Patients should be advised to avoid alcoholic beverages during this product therapy.
The vasopressor response to this product is decreased by prior administration of an α-adrenergic blocking agent such as phentolamine mesylate.
The cardiostimulating effect of this product is blocked by prior administration of β-adrenergic blocking agents such as propranolol. Propranolol may be used to treat cardiac arrhythmias occurring during administration of Phenylephrine-containing product.
Concomitant use of tricyclic antidepressants (e.g. imipramine) or guanethidine and this product may also potentiate the vasopressor effects of Phenylephrine in this product.
This product may suppress the cutaneous histamine response to allergen extracts and should be discontinue this product 4 days prior to skin testing.
This product has an additive anticholinergic action with other anticholinergic drugs, such as atropine and some antidepressants (both tricyclic antidepressants and MAOIs).
Expectorant: This product may increase renal clearance for urate, thereby lower serum uric acid levels.